trending Market Intelligence /marketintelligence/en/news-insights/trending/8AenQJdWOElzBMPEbPHIMg2 content esgSubNav
In This List

Actinium seeks orphan designation from EMA for leukemia drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Actinium seeks orphan designation from EMA for leukemia drug

Actinium Pharmaceuticals Inc. applied for orphan designation with the European Medicines Agency for Actimab-A, a drug for patients with acute myeloid leukemia age 60 and above who are ineligible for currently used induction therapies.

The drug, which already has an orphan designation in the U.S., is currently in phase 2 trial where it is being studied as a monotherapy for patients who have low peripheral blast burden. In its phase 1 trial, Actimab-A showed a 50% composite response rate.